RxDoctor Payments Data

Kaylee Howell, PA

Medical · Radcliff, KYNPI 1316317316

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 32.2% of the total.

$3,102in general payments, 2019–2025

Across 211 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$999
  • Pfizer$514
  • Biohaven Pharmaceuticals, Inc.$243
  • Lilly USA, LLC$213
  • Merck$195
  • Boehringer Ingelheim$134
  • plus $805 from 19 others

What the payments were for

  • Food & beverage$3,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,102 in reported general payments places this provider in the 75th percentile of 222 medical providers in Kentucky.

See all medical providers in Kentucky

Medicare billing

Part B allowed, 2024
$36,090
Medicare patients
101
Services billed
554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$58,716
JardianceEmpagliflozin17$17,436
JanuviaSitagliptin Phosphate20$13,428
EliquisApixaban13$13,346
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,269
SynthroidLevothyroxine Sodium13$1,027
Fluticasone Propionate41$828
Atorvastatin Calcium111$634
Albuterol Sulfate HfaAlbuterol Sulfate24$603
Levothyroxine Sodium54$601
Omeprazole32$426
Montelukast Sodium27$377
Ropinirole Hcl16$317
Lisinopril105$310
Potassium Chloride25$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$999$58,71658 claims
Boehringer IngelheimJardiance$134$17,43617 claims
MerckJanuvia$195$13,42820 claims
PfizerEliquis$514$13,34613 claims
AbbVieSynthroid$72$1,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 medical providers in Kentucky.

Other medical in Radcliff

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →